Highlights in Lung Cancer

Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer The use of osimertinib (Tagrisso, AstraZeneca) after surgery improves overall survival (OS) in patients with early-stage, EGFR-mutated […]

Hem/Onc News

Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]

Hem/Onc News

Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]

How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver

Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]

Optimal Treatment of Unresectable Stage III Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Jeffrey D. Bradley, MD S. Lee Kling Professor of Radiation Oncology Alvin J. Siteman […]

HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled

Abstract: Despite recent advances in the treatment of lung cancer, non–small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States […]